已收盤 08-11 16:00:00 美东时间
0.000
0.00%
Tango Therapeutics appoints Robert Azelby to its Board of Directors. With over 30 years of biopharmaceutical leadership, Azelby brings expertise in oncology commercialization and corporate strategy. His addition coincides with the advancement of vopimetostat, a potential PRMT5 inhibitor for pancreatic cancer, toward late-stage development. Azelby's experience will support Tango's mission to transform care for patients with MTAP-deleted cancers.
06-22 20:05
Rigetti Computing ( ($RGTI) ) has shared an announcement. On April 17, 2026, Ri...
04-22 04:42